Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.722,84
0,36%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Point Therapeutics (MM) (POTP) Point Therapeutics (MM) (POTP) Notizie

POTP

Point Therapeutics (MM) (POTP)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:POTP
DataOraFonteTitoloSimboloCompagnia
12/02/200822:15PR Newswire (US)DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of MergerNASDAQ:POTPPoint Therapeutics (MM)
12/02/200821:02Edgar (US Regulatory)Point Therapeutics Inc - Amended Statement of Ownership (SC 13G/A)NASDAQ:POTPPoint Therapeutics (MM)
11/02/200820:30Edgar (US Regulatory)Point Therapeutics Inc - Current report filing (8-K)NASDAQ:POTPPoint Therapeutics (MM)
11/02/200815:00Business WireUpdate on Point Therapeutics Merger with DARA BioSciencesNASDAQ:POTPPoint Therapeutics (MM)
08/02/200816:23Edgar (US Regulatory)Point Therapeutics Inc-Filing of certain prospectuses & communications for business combination transactions (425)NASDAQ:POTPPoint Therapeutics (MM)
04/02/200813:30PR Newswire (US)DARA BioSciences to Present at the ROTH Growth Stock ConferenceNASDAQ:POTPPoint Therapeutics (MM)
29/01/200822:30Business WirePoint Therapeutics Adjourns Meeting of Stockholders to February 12, 2008; DARA BioSciences Stockholders Approve Merger with PoinNASDAQ:POTPPoint Therapeutics (MM)
10/01/200814:00Business WirePoint Therapeutics Receives Additional Notice of Non-Compliance from NASDAQNASDAQ:POTPPoint Therapeutics (MM)
27/12/200714:30Business WirePoint Therapeutics Announces Form S-4 Registration Statement Declared Effective by SEC; Special Meeting of Stockholders Set forNASDAQ:POTPPoint Therapeutics (MM)
17/12/200723:12Edgar (US Regulatory)Point Therapeutics Inc - Registration Statement for securities to be issued in business combination transactions (S-4/A)NASDAQ:POTPPoint Therapeutics (MM)
17/12/200714:30Business WireNASDAQ Panel Grants Request of Point Therapeutics for Continued Listing on NASDAQ Capital MarketNASDAQ:POTPPoint Therapeutics (MM)
26/11/200713:13Edgar (US Regulatory)Point Therapeutics Inc - Securities Registration: Business Combination (S-4)NASDAQ:POTPPoint Therapeutics (MM)
09/11/200715:38Edgar (US Regulatory)Point Therapeutics Inc - Quarterly Report (10-Q)NASDAQ:POTPPoint Therapeutics (MM)
25/10/200713:00PR Newswire (US)DARA BioSciences, Inc. Announces New Board ChairmanNASDAQ:POTPPoint Therapeutics (MM)
17/10/200713:00PR Newswire (US)DARA BioSciences and Bayer Pharmaceuticals Corporation Sign Exclusive License AgreementNASDAQ:POTPPoint Therapeutics (MM)
09/08/200722:01Business WirePoint Therapeutics Reports Second Quarter 2007 Financial ResultsNASDAQ:POTPPoint Therapeutics (MM)
27/07/200713:30Business WirePoint Therapeutics Announces Further Management ReductionsNASDAQ:POTPPoint Therapeutics (MM)
12/07/200714:30Business WirePoint Therapeutics UpdateNASDAQ:POTPPoint Therapeutics (MM)
31/05/200714:00Business WirePoint Therapeutics Reduces Costs by Cutting Work ForceNASDAQ:POTPPoint Therapeutics (MM)
21/05/200714:00Business WireTalabostat Clinical Program Put on Clinical Hold by FDANASDAQ:POTPPoint Therapeutics (MM)
15/05/200716:02Business WireCORRECTING and REPLACING Point Therapeutics Announces Interim Analysis to be Performed on Its Phase 3 Talabostat with Alimta StuNASDAQ:POTPPoint Therapeutics (MM)
15/05/200714:01Business WirePoint Therapeutics Announces Interim Analysis to be Performed on Its Phase 3 Talabostat with Alimta StudyNASDAQ:POTPPoint Therapeutics (MM)
10/05/200714:00Business WirePoint Therapeutics Reports First Quarter 2007 Financial ResultsNASDAQ:POTPPoint Therapeutics (MM)
13/04/200714:00Business WirePoint Therapeutics Announces Preclinical Data Presentations at Upcoming American Association of Cancer Research Annual MeetingNASDAQ:POTPPoint Therapeutics (MM)
26/03/200714:24Business WirePoint Therapeutics Announces Management Change and Additional Information In Compliance With NASDAQ RulesNASDAQ:POTPPoint Therapeutics (MM)
16/03/200718:16Business WirePoint Therapeutics Reports Fourth Quarter and Year-End 2006 Financial ResultsNASDAQ:POTPPoint Therapeutics (MM)
13/03/200713:30Business WirePoint Therapeutics Receives Letter from Nasdaq Citing Non-Compliance with Minimum Bid Price RulesNASDAQ:POTPPoint Therapeutics (MM)
01/03/200713:25Business WirePoint Therapeutics Provides Clinical UpdateNASDAQ:POTPPoint Therapeutics (MM)
24/01/200714:12Business WirePoint Therapeutics Announces Resignation of William Whelan from Board of DirectorsNASDAQ:POTPPoint Therapeutics (MM)
12/01/200713:44Business WirePoint Therapeutics Provides Preliminary Results from Phase 2 Metastatic Pancreatic Cancer StudyNASDAQ:POTPPoint Therapeutics (MM)
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:POTP

La tua Cronologia

COIN
BASEETH
Base Protocol
EU
UEF6
UBS Lux Fund Solutions B...
EU
GWT
Lyxor MSCI EMU Growth DR...
LSE
65VE
Barclaysnts A45
USOTC
LNDMS
Landa App 2 (GM)
LSE
SAEM
Ish Em Imi U-a
NASDAQ
DYIIE
Dynacq
TG
BTIC
Invesco Digital Markets
BIT
UC5265
Unicredit Bank
GEMN
GRTUSD
Graph Token
NASDAQ
ASLDX
American Century Select ...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network